Inability of RUNX1/AML1 to breach AML1-ETO block of embryonic stem cell definitive hematopoiesis

Blood Cells, Molecules, and Diseases

Volumn 39, Issue 3, 2007, Pages 321-328

  Peterson, Luke F ^a   Lo, Miao Chia ^a   Okumura, Akiko Joo ^a   Zhang, Dong Er ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Acute myeloid leukemia; AML1 ETO; Embryonic stem cell; Hematopoiesis; t(8; 21)

Indexed keywords

AML 1 ETO FUSION PROTEIN; HYBRID PROTEIN; METHYLCELLULOSE; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; COLONY FORMING UNIT M; EMBRYO; EMBRYONIC STEM CELL; GENE EXPRESSION; HEMATOPOIESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA-BINDING PROTEINS; EMBRYONIC STEM CELLS; HEMATOPOIESIS; MICE; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTORS;

MUS; MUS MUSCULUS;

EID: 34748891719     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2007.06.012     Document Type: Article

References (55)

1. Licht J.D. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene 20 (2001) 5660-5679
2. Peterson L.F., and Zhang D.E. The 8;21 translocation in leukemogenesis. Oncogene 23 (2004) 4255-4262
3. Otto F., Lubbert M., and Stock M. Upstream and downstream targets of RUNX proteins. J. Cell. Biochem. 89 (2003) 9-18
4. Davis J.N., McGhee L., and Meyers S. The ETO (MTG8) gene family. Gene 303 (2003) 1-10
5. Okuda T., van Deursen J., Hiebert S.W., Grosveld G., and Downing J.R. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84 (1996) 321-330
6. Wang Q., Stacy T., Binder M., Marin-Padilla M., Sharpe A.H., and Speck N.A. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. PNAS 93 (1996) 3444-3449
7. Yokomizo T., et al. Requirement of Runx1/AML1/PEBP2alphaB for the generation of haematopoietic cells from endothelial cells. Genes Cells 6 (2001) 13-23
8. Komine O., et al. The Runx1 transcription factor inhibits the differentiation of naive CD4+ T cells into the Th2 lineage by repressing GATA3 expression. J. Exp. Med. 198 (2003) 51-61
9. Woolf E., et al. Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 7731-7736
10. Kawazu M., et al. Functional domains of Runx1 are differentially required for CD4 repression, TCR{beta} expression, and CD4/8 double-negative to CD4/8 double-positive transition in thymocyte development. J. Immunol. 174 (2005) 3526-3533
11. Iwatsuki K., et al. Runx1 promotes angiogenesis by downregulation of insulin-like growth factor-binding protein-3. Oncogene 24 (2005) 1129-1137
12. Theriault F.M., Roy P., and Stifani S. AML1/Runx1 is important for the development of hindbrain cholinergic branchiovisceral motor neurons and selected cranial sensory neurons. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10343-10348
13. Marmigere F., Montelius A., Wegner M., Groner Y., Reichardt L.F., and Ernfors P. The Runx1/AML1 transcription factor selectively regulates development and survival of TrkA nociceptive sensory neurons. Nat. Neurosci. 9 (2006) 180-187
14. Chen C.L., et al. Runx1 determines nociceptive sensory neuron phenotype and is required for thermal and neuropathic pain. Neuron 49 (2006) 365-377
15. Kramer I., Sigrist M., de Nooij J.C., Taniuchi I., Jessell T.M., and Arber S. A role for Runx transcription factor signaling in dorsal root ganglion sensory neuron diversification. Neuron 49 (2006) 379-393
16. Wang Y., Belflower R.M., Dong Y.F., Schwarz E.M., O'Keefe R.J., and Drissi H. Runx1/AML1/Cbfa2 mediates onset of mesenchymal cell differentiation toward chondrogenesis. J. Bone Miner. Res. 20 (2005) 1624-1636
17. Lian J.B., et al. Runx1/AML1 hematopoietic transcription factor contributes to skeletal development in vivo. J. Cell. Physiol. 196 (2003) 301-311
18. Zhu X., Yeadon J.E., and Burden S.J. AML1 is expressed in skeletal muscle and is regulated by innervation. Mol. Cell. Biol. 14 (1994) 8051-8057
19. Wang X., et al. Runx1 prevents wasting, myofibrillar disorganization, and autophagy of skeletal muscle. Genes Dev. 19 (2005) 1715-1722
20. Calabi F., Pannell R., and Pavloska G. Gene targeting reveals a crucial role for MTG8 in the gut. Mol. Cell. Biol. 21 (2001) 5658
21. Wildonger J., and Mann R.S. Evidence that nervy, the Drosophila homolog of ETO/MTG8, promotes mechanosensory organ development by enhancing Notch signaling. Dev. Biol. 286 (2005) 507-520
22. Zhang J., Kalkum M., Yamamura S., Chait B.T., and Roeder R.G. E protein silencing by the leukemogenic AML1-ETO fusion protein. Science 305 (2004) 1286-1289
23. Plevin M.J., Zhang J., Guo C., Roeder R.G., and Ikura M. The acute myeloid leukemia fusion protein AML1-ETO targets E proteins via a paired amphipathic helix-like TBP-associated factor homology domain. PNAS 103 (2006) 10242-10247
24. L.F. Peterson, et al. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood (2007) Apr 5; [Epub ahead of print].
25. Yergeau D.A., et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat. Genet. 15 (1997) 303-306
26. Okuda T., et al. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 91 (1998) 3134-3143
27. Miller J., et al. The core-binding factor beta subunit is required for bone formation and hematopoietic maturation. Nat. Genet. 32 (2002) 645-649
28. Castilla L.H., et al. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell 87 (1996) 687-696
29. Adya N., Stacy T., Speck N.A., and Liu P.P. The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates. Mol. Cell. Biol. 18 (1998) 7432-7443
30. Barseguian K., et al. Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 15434-15439
31. Wiles M.V., and Keller G. Multiple hematopoietic lineages develop from embryonic stem (ES) cells in culture. Development 111 (1991) 259-267
32. Fukushima-Nakase Y., Naoe Y., Taniuchi I., Hosoi H., Sugimoto T., and Okuda T. Shared and distinct roles mediated through C-terminal subdomains of acute myeloid leukemia/Runt-related transcription factor molecules in murine development. Blood 105 (2005) 4298-4307
33. Lacaud G., et al. Runx1 is essential for hematopoietic commitment at the hemangioblast stage of development in vitro. Blood 100 (2002) 458-466
34. Lacaud G., Kouskoff V., Trumble A., Schwantz S., and Keller G. Haploinsufficiency of Runx1 results in the acceleration of mesodermal development and hemangioblast specification upon in vitro differentiation of ES cells. Blood 103 (2004) 886-889
35. Schuringa J.J., Wu K., Morrone G., and Moore M.A. Enforced activation of STAT5A facilitates the generation of embryonic stem-derived hematopoietic stem cells that contribute to hematopoiesis in vivo. Stem Cells 22 (2004) 1191-1204
36. Liu B., et al. Disruption of Smad5 gene leads to enhanced proliferation of high-proliferative potential precursors during embryonic hematopoiesis. Blood 101 (2003) 124-133
37. Singbrant S., et al. Smad5 is dispensable for adult murine hematopoiesis. Blood 108 (2006) 3707-3712
38. Okumura A.J., Peterson L.F., Lo M.C., and Zhang D.E. Expression of AML/Runx and ETO/MTG family members during hematopoietic differentiation of embryonic stem cells. Exp. Hematol. 35 (2007) 978-988
39. Keller G., Kennedy M., Papayannopoulou T., and Wiles M.V. Hematopoietic commitment during embryonic stem cell differentiation in culture. Mol. Cell. Biol. 13 (1993) 473-486
40. Biggs J.R., Zhang Y., Peterson L.F., Garcia M., Zhang D.E., and Kraft A.S. Phosphorylation of AML1/RUNX1 regulates its degradation and nuclear matrix association. Mol. Cancer Res. 3 (2005) 391-401
41. Erickson P.F., Dessev G., Lasher R.S., Philips G., Robinson M., and Drabkin H.A. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease. Blood 88 (1996) 1813-1823
42. Kalev-Zylinska M.L., et al. Runx1 is required for zebrafish blood and vessel development and expression of a human RUNX1-CBF2T1 transgene advances a model for studies of leukemogenesis. Development 129 (2002) 2015-2030
43. Wildonger J., and Mann R.S. The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor. Development 132 (2005) 2263-2272
44. Klampfer L., Zhang J., Zelenetz A.O., Uchida H., and Nimer S.D. The AML1/ETO fusion protein activates transcription of BCL-2. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 14059-14064
45. R. Hines, A. Boyapati, D.E. Zhang, Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO. Blood Cells, Molecules, and Diseases (2007) Jun 20; [Epub ahead of print].
46. Peterson L.F., Yan M., and Zhang D.E. The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. Blood 109 (2007) 4392-4398
47. Meyers S., Lenny N., and Hiebert S.W. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol. Cell. Biol. 15 (1995) 1974-1982
48. Tanaka K., et al. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta (CBFbeta ) in the nucleus more efficiently than wild-type AML1. Blood 91 (1998) 1688
49. Dzierzak E. Embryonic beginnings of definitive hematopoietic stem cells. Ann. N.Y. Acad. Sci. 872 (1999) 256-264
50. Lacaud G., Robertson S., Palis J., Kennedy M., and Keller G. Regulation of hemangioblast development. Ann. N.Y. Acad. Sci. 938 (2001) 96-108
51. Gangenahalli G.U., et al. Stem cell fate specification: role of master regulatory switch transcription factor PU.1 in differential hematopoiesis. Stem Cells Dev. 14 (2005) 140-152
52. Dahl R., and Simon M.C. The importance of PU.1 concentration in hematopoietic lineage commitment and maturation. Blood Cells Mol. Diseases 31 (2003) 229-233
53. Huang G., et al. PU.1 is a critical downstream target of AML1. American Society of Hematology 46th annual meeting vol. 104[11] (2004) 107a-108a
54. Petrovick M.S., Hiebert S.W., Friedman A.D., Hetherington C.J., Tenen D.G., and Zhang D.E. Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1. Mol. Cell. Biol. 18 (1998) 3915-3925
55. Vangala R.K., et al. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood 101 (2002) 2002-2004